Nosebleeds & Ozempic: What Clinical Data Shows

Last reviewed: June 3, 2026

Last updated: June 3, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Nosebleeds are not listed as a documented adverse effect of Ozempic in FDA clinical trial data, though isolated case reports exist in post-market surveillance. GLP-1 receptor agonists like semaglutide can influence cardiovascular hemodynamics—blood pressure regulation, heart rate, and vascular tone—which theoretically could contribute to epistaxis in susceptible individuals.

If you're considering GLP-1 therapy for weight management or diabetes, understanding how your individual vascular physiology and baseline risk factors interact with these medications matters. PlexusDx's precision-wellness approach includes genetic testing that reveals predispositions in key metabolic and vascular pathways, helping you and your provider evaluate whether a compounded GLP-1 option is appropriate and how to monitor safely.

Understanding Nosebleeds and GLP-1 Mechanism of Action

Epistaxis (nosebleed) occurs when fragile blood vessels in the nasal mucosa rupture. Risk factors include nasal dryness, hypertension, anticoagulant use, and trauma. GLP-1 medications affect cardiovascular tone and blood pressure regulation, which could theoretically influence nasal vascular fragility in susceptible patients.

Ozempic and compounded semaglutide activate GLP-1 receptors throughout the body, including on vascular smooth muscle cells. This can lower blood pressure and heart rate in some patients, though the effect on nasal vessel integrity specifically is not well-characterized in published clinical literature.

Clinical Trial Data and Post-Market Safety Reporting

Systematic review of Ozempic's clinical development program—covering over 6,000 participants—found nosebleeds reported in fewer than 1% of cases, with no dose-dependent pattern. Epistaxis was not classified as a serious or common adverse event requiring black-box warning or special monitoring.

Post-market adverse event databases (FDA MedWatch, EudraVigilance) contain scattered reports of nosebleeds in GLP-1 users, but causality is often unclear. Confounding factors include concurrent medications, seasonal allergies, and individual anatomical variation. Isolated reports do not establish a causal relationship.

Data Source	Nosebleed Incidence	Clinical Significance
Ozempic Phase 3 trials	<1% (isolated cases)	Not listed as common or serious adverse event
Wegovy weight-loss trials	<1% (isolated cases)	Not associated with study discontinuation
FDA MedWatch database	Scattered reports	Causality unclear; possible confounding factors
Real-world surveillance	No systematic signal	No epidemiologic evidence of increased risk

Blood Pressure Changes and Vascular Physiology in GLP-1 Use

GLP-1 agonists typically reduce systolic blood pressure by 3–7 mmHg in clinical trials. For patients with baseline hypertension or on antihypertensive medications, this can improve cardiovascular outcomes. However, rapid blood pressure drops in some individuals—or paradoxical hypertensive episodes—may stress nasal capillary beds.

Patients with untreated or poorly controlled hypertension entering GLP-1 therapy may experience destabilization of blood pressure regulation. This vascular stress could theoretically increase nosebleed frequency, though direct evidence is lacking. Individual vascular tone and nasal mucosal fragility vary widely based on genetics, hydration status, and concurrent medications.

Who Should Discuss Nosebleed Risk With Their Provider

Patients with a personal or family history of frequent nosebleeds, uncontrolled hypertension, anticoagulant use, or platelet disorders should inform their prescriber before starting GLP-1 therapy. While nosebleeds are not a common safety signal, baseline risk stratification ensures individualized monitoring and early intervention if epistaxis develops.

If you experience new-onset or worsening nosebleeds after initiating a GLP-1 medication—whether Ozempic or a compounded alternative—contact your healthcare provider promptly. Document frequency, severity, and any accompanying symptoms (dizziness, vision changes, difficulty breathing). Your provider may adjust dosing, recommend nasal saline rinses, or evaluate for underlying causes.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test reveals predispositions in key vascular and metabolic pathways—including variants in GLP1R (rs6923761) and GIPR (rs1800437)—that may influence how your body tolerates GLP-1 therapy. While genetic predisposition does not predict nosebleed risk directly, understanding your individual metabolic fingerprint can help your provider contextualize rare side effects and adjust your treatment plan accordingly.

The genetic test examines how your body's natural GLP-1 and GIP signaling pathways function at baseline. Patients with certain genetic predispositions may experience more pronounced cardiovascular or hemodynamic effects from GLP-1 activation, which could theoretically increase susceptibility to nosebleeds in rare cases. This insight should be interpreted with a qualified healthcare provider as part of comprehensive medication review.

If you're considering compounded semaglutide or tirzepatide through PlexusDx and have concerns about rare side effects like nosebleeds, the Precision Peptide Genetic Test may help you and your provider make a more informed decision. The test provides context about your metabolic predispositions, enabling proactive monitoring and personalized dosing strategies that minimize individual risk.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.